Allt inom Interim
Nanexa publishes interim report for January – September 2023
Positive clinical and preclinical results, and secured financing with focus on NEX-22 and next steps in partner projects
Nanexa publishes interim report for January – June 2023
Strong preclinical progress with NEX-22, positive Phase 1 data with NEX-20 and several partner projects in preclinical evaluation
